AbCellera Biologics Inc.
ABCLNasdaqHealthcare · Pharmaceutical Preparations · A1 · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $75.1M | $28.8M | $38.0M | $485.4M | $375.2M | $233.2M |
| Operating income | −$217.1M | −$314.8M | −$237.2M | $216.5M | $204.4M | $156.0M |
| Net income | −$146.4M | −$162.9M | −$146.4M | $158.5M | $153.5M | $118.9M |
| Total assets | $1.36B | $1.36B | $1.49B | $1.54B | $1.32B | $1.01B |
| Total liabilities | $390.0M | $304.5M | $335.8M | $307.6M | $292.8M | $175.0M |
| Equity | $966.9M | $1.06B | $1.15B | $1.23B | $1.03B | $830.5M |
| EPS (diluted) | $-0.49 | $-0.55 | $-0.51 | $0.50 | $0.48 | $0.45 |
| Shares out. | 298.0M | 292.8M | 287.7M | 283.9M | 283.3M | 269.5M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −289.0%
- Net margin
- −194.9%
- Return on equity
- −15.1%
- Return on assets
- −10.8%
- Return on capital (ROCE)
- −16.8%
- Liabilities / assets
- 28.7%
- Debt / equity
- 0.40×
- Book value / share
- $3.24
- Revenue growth (YoY)
- 160.6%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- 4.67safe
- Accruals / assets
- −1.1%clean
- Piotroski F-Score
- 5/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 3 warning● 4 good- Operating losses (negative operating margin)
- Reported a net loss
- Negative operating cash flow
- Revenue is growing year-over-year
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 1/2Recruitingreadout ~2027-02Study Evaluating ABCL635 for Vasomotor Symptoms of Menopause
- Phase 1Recruitingreadout ~2027-04A First-in-Human Phase 1 Single-Ascending Dose Study of ABCL575 in Healthy Participants
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Baker Bros. Advisors LpPassive (13G)May 7, 2026
- Baillie Gifford & CoPassive (13G)Oct 9, 2024
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Montalbano John S.Director | May 14, 2026 | Buy | 20,000 | $4.77 |
| Thermopylae Holdings Ltd.10% owner | Feb 27, 2026 | Buy | 38,000 | $3.44 |
| Thermopylae Holdings Ltd.10% owner | Feb 26, 2026 | Buy | 177,457 | $3.27 |
| Booth AndrewOfficer — Chief Financial Officer | Feb 27, 2026 | Buy | 42,600 | $3.42 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 43.0M | 4.2 | -3.4% |
| Apr 30, 2026 | 44.5M | 6.0 | -6.8% |
| Apr 15, 2026 | 47.7M | 17.0 | -5.4% |
| Mar 31, 2026 | 50.4M | 22.7 | +0.1% |
| Mar 13, 2026 | 50.4M | 15.8 | -1.8% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operations · Regulation FD disclosureMay 11, 2026
- Results of operations · Regulation FD disclosureFeb 24, 2026
- Regulation FD disclosureJan 14, 2026
- Regulation FD disclosureDec 18, 2025
- Changed auditorNov 28, 2025
- Director / officer changeNov 12, 2025
- Results of operations · Regulation FD disclosureNov 6, 2025
- Other material eventSep 10, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.